Amgen Lung Cancer Drug Gets FDA Approval for Shorter Monitoring Periods

Amgen has received FDA approval to reduce monitoring time for patients receiving its lung cancer drug IMDELLTRA. The recommended monitoring time for the first two doses of treatment will now be between 6 and 8 hours, down from 22 to 24 hours.

This change applies only to the initial two doses administered on Cycle 1 Day 1 and Cycle 1 Day 8. For subsequent doses, monitoring recommendations remain unchanged, ranging from 6-8 hours for the third dose through Cycle 2, decreasing to 3-4 hours for Cycles 3-4 and 2 hours for Cycle 5 and beyond.

Patients are still required to stay within an hour of a healthcare setting with a caregiver present for 48 hours after the first two doses. This update may simplify treatment procedures for community oncology practices, which care for around 80% to 85% of U.S. cancer patients.